United Therapeutics Corporation (United Therapeutics), a US-based biotechnology company, has appointed Richard Giltner to its board of directors as an independent director. Giltner has more than twenty years of experience in the financial sector. His financial sector expertise includes international financial markets, financial derivatives, alternative investments and asset management.
Before beginning a one-year sabbatical on October 15, 2008, in anticipation of the birth of his second child, Julia Frances, Giltner worked as a managing director of Societe Generale Asset Management and head of the European office for its fund of hedge funds group, a role he has held since 2006. From 2003 to 2006, Giltner was the global head of foreign exchange options for the investment banking arm of Societe Generale. He has also held various other managerial roles with Societe Generale since 1991. Giltner earned a bachelor of arts degree in economics from Northwestern University in 1987.
The appointment of Giltner brings the total number of directors to nine, six of whom are independent and not affiliated with United Therapeutics. Giltner fills a newly-created seat on the board of directors.
It feels good to have a new director with extensive experience so closely aligned with the business activities of the great majority of our shareholders, said Martine Rothblatt, United Therapeutics’ chairman and chief executive officer. I feel confident that Mr. Giltner will help ensure we remain highly responsive to the interests of our shareholders.